News & Videos - AEGLEA BIOTHERAPEUTICS INC.

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire WALTHAM, Mass., Nov. 27, 2023 Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle , DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans...

Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Nov. 22, 2023 WALTHAM, Mass. , Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase...

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 9, 2023 Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β7 antibody, is on track for an expected IND filing in the first half of 2024, with interim healthy volunteer, proof of concept pharmacokinetic data expected year-end 2024 SPY002, a half-life extended anti-TL1A...

Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Nov. 3, 2023 WALTHAM, Mass. , Nov. 3, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE) PR Newswire NEW YORK, Nov. 1, 2023 NEW YORK , Nov. 1, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) on behalf of the company's shareholders. The investigation seeks to determine whether Aeglea's directors breached their fiduciary duties in connection with recent corporate actions that have caused a...

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences PR Newswire WALTHAM, Mass., Oct. 30, 2023 WALTHAM, Mass. , Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences: Guggenheim 5 th Annual...

Aeglea BioTherapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Oct. 2, 2023 WALTHAM, Mass. , Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that, Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase...

Aeglea BioTherapeutics to Participate in Upcoming September Conference PR Newswire WALTHAM, Mass., Sept. 14, 2023 WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit. Chief Operating...

Aeglea BioTherapeutics Announces Reverse Stock Split PR Newswire WALTHAM, Mass., Sept. 7, 2023 WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its...

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones PR Newswire WALTHAM, Mass., Sept. 5, 2023 Scott Burrows , former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer Heidy Abreu King-Jones , former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer & Corporate Secretary Appointments strengthen Aeglea's leadership team and provides robust financial and corporate...

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results PR Newswire WALTHAM, Mass., Aug. 11, 2023 Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including α 4b7 and TL1A programs Sale of legacy pipeline candidate, pegzilarginase, further streamlines operations and increases focus on IBD strategy $236.7 million of cash and cash...

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma PR Newswire WALTHAM, Mass., July 27, 2023 Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation Application for pegzilarginase is under review by the European Medicines Agency WALTHAM, Mass. , July 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea")...

Aeglea BioTherapeutics Announces Grant of Inducement Awards PR Newswire AUSTIN, Texas and WALTHAM, Mass., June 23, 2023 AUSTIN, Texas and WALTHAM, Mass. , June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a majority of the independent members of Aeglea's Board of Directors approved the grant of stock options to new employees (including the new members of management)...

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics PR Newswire AUSTIN, Texas and WALTHAM, Mass., June 22, 2023 Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from Paragon Therapeutics, is advancing a pipeline of product candidates, led by SPY001 and SPY002, that are potentially best-in-class antibodies targeting a 4 b 7 and TL1A,...

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results PR Newswire AUSTIN, Texas, May 11, 2023 $39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023. First Quarter 2023 Financial Results As of March 31, 2023 , Aeglea had available cash and cash equivalents, marketable securities and...

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives PR Newswire AUSTIN, Texas, April 12, 2023 Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May be Needed AUSTIN, Texas , April 12, 2023 /PRNewswire/ --...

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire AUSTIN, Texas, March 17, 2023 AUSTIN, Texas , March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023 , as...

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates PR Newswire AUSTIN, Texas, March 2, 2023 Jeffrey Goldberg , experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022 , which is expected to fund operations into the...

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire AUSTIN, Texas, Jan. 6, 2023 Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill , M.B.A., has been promoted to the newly created role of chief product officer to increase focus and efficiency in the advancement of clinical programs AUSTIN, Texas , Jan. 6, 2023 /PRNewswire/ -- Aeglea...

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire AUSTIN, Texas, Dec. 2, 2022 AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an...